The Promise of MicroRNAs as Precision Biomarkers
Isabel Moscoso,Moisés Rodríguez-Mañero,María Cebro-Márquez,Marta E. Vilar-Sánchez,Valentina Serrano-Cruz,Iria Vidal-Abeijón,María Amparo Martínez-Monzonís,Pilar Mazón-Ramos,Milagros Pedreira,José Ramón González-Juanatey,Ricardo Lage
DOI: https://doi.org/10.3390/ijms252211910
IF: 5.6
2024-11-06
International Journal of Molecular Sciences
Abstract:Cardiotoxicity (CDTX) is a critical side effect of many cancer therapies, leading to increased morbidity and mortality if not addressed. Early detection of CDTX is essential, and while echocardiographic measures like global longitudinal strain offer promise in identifying early myocardial dysfunction, the search for reliable biomarkers continues. MicroRNAs (miRNAs) are emerging as important non-coding RNA molecules that regulate gene expression post-transcriptionally, influencing key biological processes such as the cell cycle, apoptosis, and stress responses. In cardiovascular diseases, miRNAs have demonstrated potential as biomarkers due to their stability in circulation and specific expression patterns that reflect pathological changes. Certain miRNAs have been linked to CDTX and hold promise for early detection, prognosis, and therapeutic targeting. These miRNAs not only assist in identifying early cardiac injury, but also offer opportunities for personalized interventions by modulating their expression to influence disease progression. As research advances, integrating miRNA profiling with traditional diagnostic methods could enhance the management of CDTX in cancer patients, paving the way for improved patient outcomes and more tailored therapeutic strategies. Further clinical studies are essential to validate the clinical utility of miRNAs in managing CDTX.
biochemistry & molecular biology,chemistry, multidisciplinary